Allogeneic stem cell therapies produce promising results for a wide scope of biomedical research studies. Unlike autologous therapies, one healthy donor can provide quality source material for 10,000 other patients! Because these therapies have the potential to affect a considerable amount of people, the FDA has stringent guidelines for the procurement of donor blood and tissue samples. Our GTP tissue collections meet the rigorous FDA 1271 guidelines, ensuring reliable cell collection, isolation, processing and storage. StemExpress also implements extensive donor screening, testing and GTP compliance in an effort to prevent the introduction and transmission of communicable diseases.

For over a decade, StemExpress has led the way in supporting cellular therapies by supplying high quality source material for the process and development phases of research. We offer our clients vast resources, giving access to our 7 distinct donor pools. Our extensive network can provide immeasurable value, ensuring optimal donor selection for cellular material that is tailored to your specific project. At your request, StemExpress will also pre-screen your donors. Once your ideal candidate is selected, we can provide clinical grade Leukopaks from a single donor every 4 weeks.

Looking to do research in Europe? StemExpress offers customized capabilities to meet the requirements of conducting research in other countries. We follow national standards, providing clinical products that follow FDA 1271 testing performed 7 days prior to collection. We also offer EMA, HTA and PMDA compliant testing by adding on additional infectious disease testing at multiple timepoints (pre, during and post). Contact us to discuss your customized protocol needs.